N-Ethyltryptamine (NET), also abbreviated as NETP, is a tryptamine that is structurally related to N-methyltryptamine (NMT) and the psychedelic drugs N,N-dimethyltryptamine (DMT) and N,N-diethyltryptamine (DET).NET Entry in TIHKAL
Use and effects Alexander Shulgin included NET as an entry in his book TiHKAL (Tryptamines I Have Known and Loved). However, he stated that it had been subjected only to modest human trials and that no active dose level had been identified.
Pharmacology Pharmacodynamics + Target Affinity (Ki, nM) 5-HT1A 5-HT2A 38 ()99% () SERT 19a ()3,862a ()6,660a () Notes: The smaller the value, the more avidly the drug interacts with the site. Footnotes: a = Neurotransmitter release. Sources:
NET has been found to act as a potent serotonin 5-HT2A receptor full agonist and a selective serotonin releasing agent. It is inactive at the 5-HT1A receptor. The drug is also a serotonin receptor agonist in the rat uterus and stomach strip.
Chemistry Synthesis The chemical synthesis of NET has been described.
Analogues Analogues of NET include N-methyltryptamine (NMT), dimethyltryptamine (DMT), methylethyltryptamine (MET), and diethyltryptamine (DET), among others.
Society and culture Legal status Canada NET is not a controlled substance in Canada as of 2025.
See also Substituted tryptamine
References
External links NET - Isomer Design NET - TiHKAL - Erowid NET - TiHKAL - Isomer Design